33.61

2.47% 0.81

After Hours: 34.00 0.39 +1.16%

Soleno Therapeutics Inc (SLNO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Soleno Therapeutics Inc stock is traded at $33.61, with a volume of 1.17M. It is up +2.47% in the last 24 hours and down -14.72% over the past month. Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.

Previous Close:

$32.80

Open:

$32.68

24h Volume:

1.17M

Relative Volume:

0.77

Market Cap:

$1.74B

Revenue:

$190.41M

Net Income/Loss:

$20.48M

P/E Ratio:

150.85

EPS:

0.2228

Net Cash Flow:

$46.66M

1W Performance:

-8.52%

1M Performance:

-14.72%

6M Performance:

-38.60%

1Y Performance:

-31.10%

1-Day Range:

$32.34

$33.72

1-Week Range:

$32.15

$36.65

52-Week Range:

$32.15

$90.32

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name

Soleno Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (621)

Phone

650-213-8444

Address

100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA

Employee

182

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

SLNO's Discussions on Twitter

Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLNO Soleno Therapeutics Inc	33.61	1.69B	190.41M	20.48M	46.66M	0.2228
VRTX Vertex Pharmaceuticals Inc	458.05	114.72B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	737.45	78.67B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	684.50	42.38B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	311.10	41.75B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	282.72	31.33B	5.36B	287.73M	924.18M	2.5229

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-25	Initiated	Wolfe Research	Outperform
Oct-07-25	Initiated	Goldman	Buy
Aug-20-25	Initiated	Wells Fargo	Overweight
Jun-23-25	Initiated	TD Cowen	Buy
Mar-05-25	Resumed	Stifel	Buy
Dec-02-24	Reiterated	Robert W. Baird	Outperform
Dec-02-24	Reiterated	Stifel	Buy
Sep-03-24	Initiated	H.C. Wainwright	Buy
May-10-24	Initiated	Robert W. Baird	Outperform
Feb-05-24	Initiated	Piper Sandler	Overweight
Jan-23-24	Initiated	Stifel	Buy
Nov-21-23	Resumed	Guggenheim	Buy
Sep-29-20	Initiated	Guggenheim	Buy
Jan-10-20	Initiated	Craig Hallum	Buy
Dec-23-19	Initiated	Oppenheimer	Outperform
Feb-13-18	Reiterated	Maxim Group	Buy

View All

Soleno Therapeutics Inc Stock (SLNO) Latest News

07:45 AM

Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman - marketscreener.com

07:45 AM

07:44 AM

Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman - GlobeNewswire Inc.

07:44 AM

07:22 AM

Soleno Lawsuit Puts DCCR Safety Disclosures And Growth Story Under Scrutiny - simplywall.st

07:22 AM

06:11 AM

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure ... - Caledonian Record

06:11 AM

06:10 AM

Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors - GlobeNewswire

09:00 AM

08:11 AM